Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581851 | 0.83 | KCNH2 (0.36) | KCNH2CXCR4PARP1NOS1NOS2 | |
| SCHEMBL31481285 | 0.83 | KCNH2 (0.36) | KCNH2CXCR4PARP1NOS1NOS2 | |
| Ammonia Solution, Strong SCHEMBL7989286 | 0.82 | KCNH2 (0.35) | KCNH2CXCR4PARP1NOS1NOS2 | |
| SCHEMBL19069604 | 0.81 | PARP1 (0.35) | KCNH2CXCR4PARP1 | |
| SCHEMBL20436448 | 0.80 | KCNH2 (0.34) | KCNH2CXCR4PARP1NOS1NOS2 | |
| SCHEMBL27270503 | 0.80 | PARP1 (0.37) | KCNH2CXCR4PARP1HRH4CHRNB2 | |
| SCHEMBL15318642 | 0.80 | TSHR (0.35) | KCNH2CXCR4PARP1NOS1NOS2 | |
| SCHEMBL18710696 | 0.78 | KCNH2 (0.33) | KCNH2CXCR4PARP1NOS1NOS2 | |
| SCHEMBL14599963 | 0.78 | NOS1 (0.35) | KCNH2CXCR4PARP1NOS1NOS2 | |
| SCHEMBL23343749 | 0.78 | ADORA2A (0.37) | KCNH2CXCR4PARP1NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894803-B2 | Multi-functionalized polysaccharide compounds and use thereof for targeting the cation-independent mannose 6-phosphate receptor | NANOMEDSYN (FR) | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894803-B2 | Multi-functionalized polysaccharide compounds and use thereof for targeting the cation-independent mannose 6-phosphate receptor | M6PR, IGF2R, MPI | KCNH2 3938/4885CXCR4 455/4885PARP1 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.